Even though the prognostic/predictive role of TP53 and PIK3CA mutations has been addressed in a considerable number of studies, information regarding their role with respect to specific breast cancer subtypes within the context of adjuvant trials remains limited. This evidence concerns the gene PIK3CA and breast cancer.